Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naohiro Oda

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Respiratory Investigation|July 22, 2023
Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancerToshio Kubo, Eiki Ichihara, Daijiro Harada, et al.
Respiratory Research|May 16, 2021
Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in miceDaisuke Morichika, Akihiko Taniguchi, Naohiro Oda, et al.
Respiratory Investigation|February 28, 2020
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidoneHisao Higo, Nobuaki Miyahara, Akihiko Taniguchi, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2016
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experienceKenichiro Kudo, Katsuyuki Hotta, Akihiro Bessho, et al.
Cancer Science|July 30, 2020
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance statusHirohisa Kano, Eiki Ichihara, Daijiro Harada, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2016
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experienceNaohiro Oda, Katsuyuki Hotta, Hiroshige Yoshioka, et al.
Cureus|July 24, 2025
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 StudySho Saeki, Katsuyuki Hotta, Shinya Sakata, et al.
Cancers|December 23, 2022
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational StudyTomoka Nishimura, Eiki Ichihara, Toshihide Yokoyama, et al.
International Journal of Clinical Oncology|May 9, 2022
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, et al.
Plos One|October 26, 2023
A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infectionEiki Ichihara, Kou Hasegawa, Kenichiro Kudo, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Respiratory Investigation|July 22, 2023
Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancerToshio Kubo, Eiki Ichihara, Daijiro Harada, et al.
Respiratory Research|May 16, 2021
Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in miceDaisuke Morichika, Akihiko Taniguchi, Naohiro Oda, et al.
Respiratory Investigation|February 28, 2020
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidoneHisao Higo, Nobuaki Miyahara, Akihiko Taniguchi, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2016
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experienceKenichiro Kudo, Katsuyuki Hotta, Akihiro Bessho, et al.
Cancer Science|July 30, 2020
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance statusHirohisa Kano, Eiki Ichihara, Daijiro Harada, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2016
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experienceNaohiro Oda, Katsuyuki Hotta, Hiroshige Yoshioka, et al.
Cureus|July 24, 2025
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 StudySho Saeki, Katsuyuki Hotta, Shinya Sakata, et al.
Cancers|December 23, 2022
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational StudyTomoka Nishimura, Eiki Ichihara, Toshihide Yokoyama, et al.
International Journal of Clinical Oncology|May 9, 2022
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, et al.
Plos One|October 26, 2023
A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infectionEiki Ichihara, Kou Hasegawa, Kenichiro Kudo, et al.
Pageof 7